NORTHBROOK, Ill.--(BUSINESS WIRE)--Endevica Bio, a company developing first-in-class peptide drug candidates with better safety and efficacy properties, has closed a $10 million Series B funding. The ...

DelveInsight’s ‘Cancer Cachexia Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia epidemiology in the 7MM, i.e., the ...

Jericho, New York, April 02, 2026 (GLOBE NEWSWIRE)-- Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage therapeutics company, today announced that it is ...

It has been known for many years that advanced cancer is associated with a wasting syndrome that speeds the demise of patients. About one-quarter to a third of patients with advanced cancer develop ...

HOUSTON, Feb. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...

The investigational drug ponsegromab — which inhibits growth differentiation factor 15 (GDF-15), a cytokine elevated in cancer cachexia — increases weight, appetite, and physical activity in patients ...

Cachexia is a paraneoplastic syndrome of unintentional adipose and muscle tissue wasting with severe impacts to functionality and quality of life. Although health inequities across minority and ...

Researchers discovered a drug that safely and effectively helped cancer patients when they suffered from cachexia (ku-KEK-see-uh), a common condition related to cancer that involves weight loss and ...

Cachexia in older SCLC patients leads to inferior survival rates and increased treatment complications, such as dose reductions and incomplete chemotherapy courses. Patients with cachexia had ...

Eating disorders are often thought of as body image disorders with symptoms of food restriction and purging. In most cases, the goal of these behaviors is to prevent weight gain. Not all eating ...